Avicanna Launches Medical Cannabis Study via MyMedi.ca

Avicanna Inc. is set to embark on a comprehensive medical cannabis study via its MyMedi.ca platform. This initiative will be led by Dr. Hance Clarke, who is both the President of The Canadian Pain Society and part of the Canadian Consortium for the Investigation of Cannabinoids. This prospective, non-interventional, and observational study aims to enroll 1,000 patients from across Canada. The primary goal is to understand the therapeutic potential of medical cannabis and its impact on conditions such as pain, sleep disorders, anxiety, depression, and epilepsy. The study will utilize validated questionnaires to assess the effects of various medical cannabis products and evaluate changes in the use of concomitant medications over a 24-week period.

Dr. Clarke expressed his enthusiasm, stating, "I am pleased that Avicanna has stepped up to support this important work. We must continue to gather data and better understand what effects these cannabis products are having on Canadian patients that are approaching cannabis for therapeutic benefit."

Dr. Karolina Urban, Executive Vice President of Medical Affairs, also highlighted the significance of the MyMedi.ca platform. She noted, “MyMedi.ca medical cannabis care platform was established with a number of goals that included access to medical cannabis, providing patient support and education, and facilitating research on cannabinoid medicines. We are excited to support the Study and hope that the results of this study will provide data, evidence, and increase our understanding of the potential impacts of medical cannabis across a range of conditions that may facilitate the incorporation of medical cannabis into standard of care.”

Initially initiated by Medical Cannabis by Shoppers, the study is part of Avicanna’s commitment to ongoing patient care and the advancement of medical research. The MyMedi.ca platform will offer the necessary infrastructure, patient support, and educational resources for all participating healthcare professionals nationwide. Patients participating in the study will have access to a range of products, including Avicanna’s RHO Phyto formulary and offerings from select licensed producers supporting the study.

About Avicanna Inc., it is a commercial-stage biopharmaceutical company focused on developing, manufacturing, and commercializing cannabinoid-based products on a global scale. The company’s scientific platform includes R&D and clinical development, leading to the commercialization of over thirty proprietary, evidence-based products across four commercial pillars.

The Medical Cannabis formulary known as RHO Phyto™ includes a wide range of proprietary products designed for various delivery methods such as oral, sublingual, topical, and transdermal, with differing cannabinoid ratios. This formulary is well-established within Canada and continues to expand internationally.

Avicanna’s MyMedi.ca platform aims to enhance the medical cannabis patient journey by providing comprehensive patient support programs, specialty services, and educational resources for the medical community. The platform is operated by Northern Green Canada Inc. and facilitates the incorporation of medical cannabis into healthcare regimens.

In addition to these initiatives, Avicanna has developed a pharmaceutical product pipeline under the brand Trunerox™, which aims to address unmet medical needs in dermatology, chronic pain, and neurological disorders. Trunerox™ was recently approved in Colombia as an adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome.

Avicanna’s active pharmaceutical ingredients are provided by its subsidiary Santa Marta Golden Hemp SAS, which focuses on high-quality CBD, THC, and CBG for international partners in food, cosmetics, medical, and pharmaceutical sectors.

This study represents a significant step in understanding the real-world application of medical cannabis and could pave the way for its broader incorporation into standard medical practices.